The FDA has given Seragen Inc. (NASDAQ:SRGN) the go-ahead tobegin clinical trials on its drug for treating severe rheumatoidarthritis and a variety of lymphomas -- cutaneous T-celllymphoma, Hodgkin's disease, and non-Hodgkin's lymphoma --that express interleukin-2 receptors. The compound,DAB389IL-2, is the company's latest version of itsinterleukin-2 receptor-targeted fusion toxin. It is a singleprotein with three domains, which the Hopkinton, Mass.,company grows in E. coli, said Helen Maslocka, director ofcorporate communications.

(c) 1997 American Health Consultants. All rights reserved.